Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

By P. Gionchetti, F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli, M. Campieri. Gastroenterology, 2000

1,534 citations recorded by the source corpus.

Subfields: Food Science, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/9be73671a6408a961d7d8976914633c1dc8265fe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

1. T. Kanai
2. K. Matsuoka
3. G. Schatzmayr
4. R. Sartor
5. Herbert Tilg

In Genetics

1. T. Kanai
2. K. Matsuoka
3. S. Bischoff
4. R. Sartor
5. Herbert Tilg
6. J. Turner

In Molecular Biology

1. S. Bischoff
2. R. Sartor
3. T. Kanai
4. Herbert Tilg
5. K. Matsuoka
6. J. Turner

Citations in the corpus

• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis (2006, background): “Four, different probiotic preparations produce variable responses in the same clinical setting”
• Probiotics and their fermented food products are beneficial for health (2006, background): “…Bifidobacterium bifidum and Strep. thermophilus (Hilton et al. 1977; Savaiano and Levitt 1987; Isolauri et al. 1991; Saavedra et al. 1994; Salminen et al. 1996; Saxelin 1997; Aiba et al. 1998; Gionchetti et al. 2000a; Gorbach 2000; Pochapin 2000; Shanahan 2001; Solga 2003; Tomas et al. 2004).”
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee (2010, background): “An oral probiotic formulation VSL-3 (containing lactobacilli, bifidobacteria, and Streptococcus salivarius ) was effective in the prevention of pouchitis for up to 1 year after surgery (”
• Intestinal permeability – a new target for disease prevention and therapy (2014, background): “The next important finding was that the probiotic mixture VSL#3 reduces and protects against pouchitis in patients with UC [185,186].”
• Probiotic use in clinical practice: what are the risks? (2006, background): “lactis Bb12 and Lactobacillus reuteri (ATCC 55730) at 1 10(7) CFU/g in a cow milk formula] to prevent diarrheal illness in infants attending childcare (8, 9).”
• The gut microbiota and inflammatory bowel disease (2014, positive): “#3 in the prevention of recurrence in patients with chronic relapsing pouchitis [60, 61].”
• Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease (2004, background): “45 47 71 72 31 One of the species excised from the SSCP gel showed a close phylogenetic relationship to the Enterobacteriaceae group.”